



This is a repository copy of *An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/117149/>

Version: Accepted Version

Article:

Tappenden, P. orcid.org/0000-0001-6612-2332, Sadler, S. orcid.org/0000-0001-5935-8507 and Wildman, M. (2017) An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis. *PharmacoEconomics*, 35 (6). pp. 647-659. ISSN 1170-7690

<https://doi.org/10.1007/s40273-017-0500-x>

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

AN EARLY HEALTH ECONOMIC ANALYSIS OF THE POTENTIAL COST-EFFECTIVENESS OF AN ADHERENCE INTERVENTION TO IMPROVE OUTCOMES FOR PATIENTS WITH CYSTIC FIBROSIS

Short title: Cost-effectiveness of CF adherence intervention

List of authors

Paul Tappenden, Reader in Health Economic Modelling, School of Health and Related Research, University of Sheffield

Susi Sadler, Research Associate, School of Health and Related Research, University of Sheffield

Martin Wildman, Consultant in Respiratory Medicine and Adult Cystic Fibrosis, Sheffield Teaching Hospitals NHS Foundation Trust

Corresponding author

Dr Paul Tappenden, Reader in Health Economic Modelling, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, England.

Tel: +44 114 2220855

Fax: +44 114 2724095

Email: p.tappenden@sheffield.ac.uk

ABSTRACT

Background: Cystic fibrosis (CF) negatively impacts upon health-related quality of life (HRQoL) and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline.

Methods: A state transition model was developed to assess the cost-effectiveness of an intervention aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT). The model estimates the costs and health outcomes for each option from the perspective of the UK National Health Service (NHS) and Personal Social Services (PSS) over a lifetime horizon. Health gains are valued in terms of quality-adjusted life years (QALYs) gained. Forced Expiratory Volume in 1 Second (FEV₁) trajectories are predicted over three lung function strata: (i) FEV₁ ≥70%; (ii) FEV₁ 40-69%, and; (iii) FEV₁ <40%. Additional states are included to represent post-lung transplantation and dead. The model was populated using CF Registry data, literature and expert opinion. Costs were valued at 2016 prices. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses.

Results: If effective, the adherence intervention is expected to produce an additional 0.19 QALYs and cost savings of £64,078 per patient. Across all analyses, the intervention dominated current care. Over a 5-year period, the intervention is expected to generate cost savings of £49.5million for the estimated 2,979 CF patients with *Pseudomonas aeruginosa* currently aged 16 or above in the UK. If applied to a broader population of adult CF patients receiving any nebulised therapy, the expected savings could be considerably greater.

Conclusions: If effective, the adherence intervention is expected to produce additional health gains at a lower cost than current CF care. The economic analysis should however be revisited upon completion of the full RCT. More generally, the analysis suggests that considerable gains could be accrued through the implementation of adherence interventions which shift care from expensive hospital-based rescue to community-based prevention.

KEY POINTS FOR DECISION-MAKERS

- Based on a pre-trial analysis of the CFHealthHub study, the use of an effective adherence intervention for CF is expected to produce an additional 0.19 QALYs and cost savings of £64,078 per patient compared with current CF care. Over a 5-year period, this corresponds to cost savings of approximately £49.5million for the estimated 2,979 CF patients with *Pseudomonas aeruginosa* currently aged 16 or above in the UK.
- If the adherence intervention benefits a broader population of CF patients who are receiving nebulised antibiotics and/or mucolytics and are aged 16 or over (likely to represent approximately 5,800 patients), the 5-year cost savings to the NHS are expected to be in excess of £96million. Given existing uncertainty, it will be important to revisit this economic analysis upon completion of the full CFHealthHub RCT.

1. INTRODUCTION

Cystic fibrosis (CF) is an inherited condition characterised by the abnormal transport of chloride ions (Cl⁻) across transporting epithelia. This leads to the production of thick sticky mucus in the lungs, pancreas, liver, intestine, and reproductive tract, and an increase in the salt content in sweat. More than 10,000 children and adults in the UK have CF [1]. Whilst CF limits life expectancy, survival is increasing, and in 2015, approximately 6,475 CF sufferers in the UK were older than 16 years of age [1]. Amongst other problems, for example poor digestion, patients with CF are susceptible to lung infections, in particular, *Pseudomonas aeruginosa*. This is thought to be because the thick mucus makes it difficult for the body to clear inhaled bacteria, and because people with CF have an increased airway inflammatory response to pathogens [2]. People with CF often develop intermittent infections during childhood, which can be treated and even eradicated with nebulised or inhaled antibiotics. As infection develops, however, patients may reach a chronic stage whereby eradication is no longer possible due to the formation of biofilms [3]. In such cases, ongoing inhaled antibiotic treatment must be continued permanently. Patients commonly also require other treatments including inhaled mucolytics, bronchodilators, steroids, and physiotherapy [1]. Treatment is time consuming and burdensome [4], with administration of nebulised antibiotics taking up to an hour per day whilst patients are well and longer during periods of ill health. In addition, patients also experience pulmonary exacerbations which require treatment with intravenous (i.v.) antibiotics which are administered either at home or in hospital. In either case, this treatment compromises the patient's ability to attend school or work and leads to increased health care costs.

Adherence to preventative nebulised CF treatments is estimated at 48%, based on medication possession ratio (MPR) data in 3,287 people with CF aged 6 years and above in the US [5]. This is a measure of persistent adherence as these are chronic medications which are taken long-term [6]. These data show that adherence is inversely related to age. Importantly, MPR measures only medication that is collected from the pharmacy and cannot measure whether that medication is ever taken. Objective UK data using chipped nebulisers in adults goes beyond the coarse MPR adherence metric to determine objectively how much treatment is actually taken. These data suggest a lower median adherence rate of 36% in nebulisers that are brought to clinic to be downloaded [7]. It is also important to ensure that estimated adherence rates take into account the patient's clinical status ("normative adherence") and includes both nebulisers brought to clinic and the more difficult to obtain nebulisers left at home; UK data reported by Hoo et al suggest that when all nebulised devices are included, normative adherence in adult clinics may be as low as 33% [8].

Treatments only work if they are taken, and estimates of drug effectiveness are usually derived from randomised controlled trials (RCTs) whereby strict inclusion criteria and trial procedures typically produce high adherence rates. A recent review of adherence to CF treatments within clinical trials by

Pugatsch et al [9] reported an adherence rate of 80% as an aggregate estimate across the population over the entire duration of the studies (mean duration 7.3 months; range 2-24 months). The methodology for adherence measurement varied between trials, but was typically undertaken at frequent intervals across the trials and can be considered as a measure of persistent adherence [6]. Although there was a tendency for some reduction over time, adherence remained high across all phases of follow-up. Based on MPR data, it has been shown that CF patients with poor adherence (MPR <50%) have significantly higher healthcare costs than patients with good adherence (MPR>80%); most of the excess costs in poor adherers are related to hospital admission for i.v. rescue therapy to treat pulmonary exacerbations [5]. A meta-analysis reported by Demonceau et al assessed feedback of objective adherence data in various conditions across 5,237 patients; this study demonstrated that such feedback could increase adherence by around 20%, with a further 8% improvement if simple problem solving was added [10].

The ongoing CFHealthHub ACtiF trial (Adherence to treatment in adults with Cystic Fibrosis) is currently assessing an intervention to improve outcomes for CF patients by empowering self-management and improving adherence to nebulised therapy via the use of chipped nebulisers which have the capacity to directly monitor adherence levels, combined with an intervention to support problem solving, habit formation and self-efficacy undertaken by a member of the multidisciplinary team at regular appointments [11]. The hypothesis underpinning this RCT is that increasing adherence will reduce the number of exacerbations experienced by CF patients. Reducing the number of exacerbations experienced by CF patients may also impact on their rate of lung function deterioration.

This paper presents an early health economic evaluation of the expected cost-effectiveness of the adherence intervention compared with current clinical care, in advance of the completion of the full CFHealthHub ACtiF RCT (due to complete in September 2019). More generally, this analysis provides a formal quantification of the potential gains which could be accrued by improving disease control in CF through improved adherence.

2. METHODS

2.1 Scope of the analysis

A model-based cost-utility analysis was undertaken to assess the incremental cost-effectiveness of the adherence intervention versus standard care in adult CF patients receiving traditional nebulised or dry powder inhaled (DPI) antibiotics from the perspective of the National Health Service (NHS) and Personal Social Services (PSS) over a lifetime horizon. The intervention relates to a newly-developed nebuliser with the capacity to monitor and report adherence levels (developed as part of the CFHealthHub ACtiF programme [11]), combined with a behavioural intervention undertaken by a physiotherapist at regular appointments. Health benefits are assessed in terms of quality-adjusted life

years (QALYs) gained. All costs and health outcomes were discounted at a rate of 3.5% per annum [12]. Costs were valued at 2016 prices.

2.2 Model structure

The analysis uses a state transition approach, based on the structure of a previously published health economic model developed to assess the cost-effectiveness of DPIs for CF patients with chronic *Pseudomonas aeruginosa* [13;14]. The model was populated using analyses of individual patient data (IPD) from the UK CF Registry [15], literature and expert opinion. The model estimates Forced Expiratory Volume in 1 Second (FEV₁) percent predicted trajectories over three strata of lung function: (1) FEV₁ ≥70%; (2) FEV₁ 40-69%, and; (3) FEV₁ <40% (Figure 1). Additional health states are included to represent post-lung transplantation and dead. During each annual cycle, patients may remain in their current FEV₁ state, transit to an improved or worsened FEV₁ state or die. A small proportion of patients with FEV₁<40% may undergo lung transplantation and do not subsequently receive further nebulised/DPI treatment. HRQoL is modelled according to FEV₁ stratum and transplant history, with disutilities applied according to the proportion of time spent receiving i.v. antibiotics to manage CF exacerbations. A half-cycle correction is applied to account for the timing of events. Total QALYs are calculated as the total sojourn time in each health state weighted by state-specific utility scores, less any QALY losses resulting from exacerbations. The model conservatively assumes that there is no survival difference between the intervention and comparator groups. Costs include UK CF tariff treatment costs, high-cost drug acquisition, costs of i.v. days spent in hospital and associated i.v. antibiotic acquisition, transplantation costs and costs associated with the adherence intervention. All other costs are assumed to be captured in the CF banding tariff [16].

The model employs the following assumptions:

- Patients in any FEV₁ stratum can progress/regress to any other FEV₁ stratum
- Reductions in exacerbations impact upon progression rates between FEV₁ strata
- The probability of experiencing exacerbations differs by FEV₁ stratum
- A small proportion of patients with FEV₁ <40% undergo lung transplant, whilst those ineligible for transplant continue to receive nebulised/DPI therapy
- Reductions in lung function and the incidence of exacerbations impact upon HRQoL
- The adherence intervention will impact upon the incidence of exacerbations and FEV₁ transitions
- Exacerbation rates and transition rates between FEV₁ strata are time-invariant
- The costs of “high-cost therapies” are independent of adherence to those therapies.

Figure 1: Model structure

[INSERT FIGURE 1 HERE]

2.3 Evidence used to inform the model parameters

Model parameters and their associated distributional properties are summarised in Table 1.

Table 1: Summary of model parameters

[INSERT TABLE 1 HERE]

Patient characteristics

The population is assumed to be 16 years of age at model entry. The initial distribution of patients across the health states was based on recorded FEV₁ in 2013 from the CF Registry (the most recent year available for the analysis).

Transition probabilities

Transition probabilities were derived from IPD from the CF Registry for a total of 10,344 patients between 2007 and 2013 [15]. The overall dataset was restricted to those patients who have been recorded (at least once) as having ‘intermittent’ or ‘chronic’ *Pseudomonas aeruginosa* status (n=7,518). Fifty-three percent of these patients were male, and their average age on first appearing in the 2007-2013 dataset was 19 years (range 0-82 years). At baseline, the proportion of patients in each FEV₁ stratum was as follows: FEV₁<40%=0.13; FEV₁ 40-69%=0.32; FEV₁>70%=0.55. Of these, 6,788 had at least one recorded FEV₁ assessment and 1,700 had measures for all seven years. Longitudinal regression was undertaken using the methods described by Jung et al [23]; this involved the estimation of a series of ordered logit models which give the log odds of being in a given FEV₁ group post-transition, given the time (in days) between observations, the annual rate of hospital i.v. days and the patient’s age. One model was estimated for each of three possible FEV₁ starting states and the model outputs were converted into annual probabilities. This approach allowed for the inclusion of patients who had between 2 and 7 entries in the registry, even if there were gaps before, between, or after review entries. Patients who left the registry were excluded from the analysis. The time variable (days since last visit) allows for the calculation of annual transitions despite the fact that sample intervals varied in the raw registry data. The lagged rate of i.v. days variable allowed for the investigation of the effect of exacerbations on FEV₁ progression. A number of models were tested with both age and sex as covariates. Age was statistically significant in most models, but sex was not significant, therefore age was retained in the final model.

Mean days on i.v. antibiotics per year

Mean days in hospital or at home receiving i.v. antibiotics for each FEV₁ group were estimated from the same group of patients with *Pseudomonas aeruginosa* in the CF Registry used to derive transition probabilities [15].

Effectiveness of the adherence intervention

The intervention is assumed to reduce the number of days on i.v. antibiotics, leading to changes in the transition rates between the FEV₁ strata. The CFHealthHub ACtiF trial is powered to detect a reduction of one exacerbation per annum, based on a previous trial of long-term inhaled hypertonic saline for CF (Elkins et al [17]); this treatment effect is assumed to reflect the minimum clinically important difference. Assuming one exacerbation is equivalent to 14 days of home or hospital i.v. antibiotics [24;25], when applied to the whole CF Registry cohort with *Pseudomonas aeruginosa*, this equates to a 55% reduction in days spent receiving i.v. antibiotics. Uncertainty surrounding the relative risk reduction in i.v. days was assumed to broadly reflect that observed in the Elkins et al trial [17], but the 95% confidence interval [CI] was widened to account for additional uncertainty surrounding the effectiveness of the adherence intervention (mean relative risk=0.45, standard error=0.09). Post-intervention exacerbation rates were also applied to the logit models to derive FEV₁ transition probabilities for the adherence intervention.

CF mortality

The CF Registry does not include sufficient data to allow for the robust derivation of estimates of long-term survival for CF patients [15]. Instead, survival estimates were based on an analysis reported by Dodge et al [20]. This study reported survival data up to the end of 2003 for all subjects with CF born in the UK in the period 1968-1992 collated via active enquiry of CF clinics and other hospital consultants. The published survival curves for males and females were digitised and patient-level time-to-event data were reconstructed using methods reported by Guyot et al [26]. Parametric survivor functions (exponential, log normal, log logistic, Weibull, Gompertz and generalised gamma) were fitted to the replicated data to extrapolate beyond the observed follow-up period. Model discrimination was undertaken using visual inspection, an examination of the goodness-of-fit statistics for each survivor function (the Akaike Information criterion [AIC] and the Bayesian Information Criterion [BIC]), together with subjective clinical judgement regarding the plausibility of the extrapolated portion of each parametric curve. On the basis of clinical plausibility, the Gompertz survivor function was selected for use in the model. Uncertainty surrounding the parameters of the survivor function was modelled using independent normal distributions with the 95% CI width calibrated such that it was similar to that observed for patients in the current CF Registry population. The same function was applied to the intervention and comparator groups, hence the adherence intervention is not assumed to impact on patient survival.

Probability of transplantation

The probability that a patient with FEV₁ <40% will undergo a lung transplant during each cycle was estimated based on data from the UK CF Registry [1] and the US Cystic Fibrosis Foundation, assuming a 2-3% lifetime probability of undergoing lung transplantation [13;14].

HRQoL

The selection of studies used to inform HRQoL parameters within the model was based on a previous systematic review [9]. Health state utilities associated with each FEV₁ stratum and the disutility associated with exacerbations were based on a UK utility valuation study reported by Bradley et al [18]; within this study, the 3-level Euroqol-5 Dimensions (EQ-5D) and the Cystic Fibrosis Questionnaire-Revised (CFQ-R) were administered to patients aged ≥ 16 years with CF and chronic *Pseudomonas aeruginosa* and who were taking nebulised or oral antibiotics. The utility score for patients who have undergone lung transplantation was taken from a cross sectional utility valuation study involving 3-level EQ-5D assessments in patients awaiting lung transplantation and transplant recipients attending follow up clinics in the UK [19].

Resource costs

The model includes costs associated with CF tariff banding, high cost antibiotic therapies, hospital i.v. days, i.v. antibiotics, transplantation and the adherence intervention. The proportion of patients in each band of the CF tariff according to FEV₁ stratum were derived from the CF Registry [15]; banding tariff costs were taken from the latest NHS National Tariff [16]. Usage of specific antibiotic products was estimated from the CF Registry dataset [15]. The analysis assumes that patients are prescribed these treatments according to their licensed dosing schedules rather than according to patient adherence levels. Unit costs for nebulised and DPI antibiotics were derived from British National Formulary (BNF) 2016 [21]. Transplantation costs were based on personal communication (Kim Cox, NHS England). The costs of i.v. antibiotics (tobramycin and ceftazidime) were sourced from Sheffield Teaching Hospitals (personal communication: Tim Gleeson, Sheffield Teaching Hospitals, England, 2016). The cost of a hospital i.v. day was based on NHS Reference Costs 2014/15; as there is no inpatient cost relating to CF exacerbations, the daily cost associated with a long stay inpatient admission for bronchiectasis with complications and comorbidity score 0 was assumed (daily cost = £361.68) [22]. The model assumes that 54% i.v. days take place in hospital; the remaining 46% are assumed to take place at the patient's home and do not lead to additional costs for the NHS (personal communication: Tim Gleeson, Sheffield Teaching Hospitals, England, 2016). The costs of the adherence intervention were assumed to include a once-only cost for data transfer hardware of £121.20 plus an ongoing annual data transfer cost of £583.44 per patient (personal communication: Martin Wildman, Sheffield Teaching Hospitals, England, 2016). The analysis assumes that the training and implementation costs associated with the behavioural impact component of the adherence intervention would be absorbed into routine clinic appointments undertaken by CF healthcare practitioners and therefore these costs have been excluded.

Model evaluation methods

Cost-effectiveness was expressed in terms of the incremental cost per QALY gained. Uncertainty surrounding the cost-effectiveness of the adherence intervention was explored using deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). The PSA included all uncertain model parameters and was implemented using simple Monte Carlo sampling methods (2,000 random iterations). DSAs were conducted to explore the impact of alternative time horizons, assumptions of a less durable treatment effect, an assumption that the intervention impacts on exacerbation rates only, reduced impacts on exacerbation rates, and alternative assumptions regarding cost and utility parameters. In addition, a further scenario was conducted whereby treatment costs were calculated according to expected adherence levels in each group, based on Daniels et al [7] (36% drug consumption in current CF care group) and Demonceau et al [10] (63.7% drug consumption for the adherence intervention group).

Model validation methods

Several measures were taken to verify the implemented model and to ensure the credibility of its underlying conceptual basis. These included internal peer review by clinical experts, scrutiny of the implemented model coding and formulae, checking the accuracy of all model inputs against sources, investigating potentially discrepant or unexpected results identified through black box testing and double-programming of the deterministic model. Whilst the results of the CFHealthHub ACTiF trial will not be available until at least September 2019, once available, this evidence will allow the economic analysis to be updated using prospectively collected randomised data; this will also enable the comparison of the predictions of the pre-trial and post-trial analyses.

3. RESULTS

3.1 Central estimates of cost-effectiveness

Table 2 presents the central estimates of cost-effectiveness for the adherence intervention versus current CF care based on the probabilistic version of the model.

Table 2: Central estimates of cost-effectiveness (probabilistic)

[INSERT TABLE 2 HERE]

The probabilistic version of the model suggests that, if effective, the adherence intervention is expected to produce an additional 0.19 discounted QALYs per patient and cost-savings of approximately £64,078 per patient over their remaining lifetime; hence, the adherence intervention is expected to dominate current care. The cost savings predicted by the model are driven by a small shift in CF banding resulting from improvements in predicted FEV₁ trajectory, together with a significant reduction in the expected number of hospital i.v. days (accounting for savings of approximately

£70,000 per patient). As shown in the cost-effectiveness plane (Figure 2), whilst there is considerable uncertainty surrounding the health gains associated with the intervention, the probabilistic analysis consistently indicates that the adherence intervention is expected to produce substantial cost savings. Across willingness-to-pay thresholds of between £0 and £100,000 per QALY gained, the probability that the adherence intervention produces more net benefit than current care is expected to be 1.0.

3.2 Sensitivity analysis results

Across all of the DSAs, the adherence intervention is expected to dominate current care (Table 3). This includes the highly pessimistic situation whereby the costs of high cost drugs calculated exactly according to the level patient adherence, based on Daniels et al [7] and Demonceau et al [10]. Even in this unlikely scenario, the savings associated with costs of i.v. hospital days avoided outweigh the additional costs of drug therapy due to increased patient adherence to nebulised and inhaled therapy. Assuming that treatment costs are independent of adherence levels, the sensitivity analysis suggests that over the course of 5-years, the model estimates discounted cost savings of £16,623 per patient; this is equivalent to approximately £49.5million for the estimated 2,979 CF patients with *Pseudomonas aeruginosa* currently aged 16 or above in the UK. Should the intervention benefit a broader population of CF patients who are receiving nebulised antibiotics and/or mucolytics and are aged 16 or over (likely to represent approximately 5,800 patients), the 5-year cost savings to the NHS are expected to be in excess of £96million.

Table 3: Deterministic sensitivity analysis results

[INSERT TABLE 3 HERE]

Figure 2: Cost-effectiveness plane

[INSERT TABLE 3 HERE]

4. DISCUSSION

This study represents the first health economic analysis of an intervention targeted at increasing patient adherence to nebulised/DPI treatments in CF. The results of the analysis suggest that the adherence intervention has the potential to produce considerable health gains as well as cost savings for the NHS, thereby dominating current CF care. The principal driver of the anticipated cost savings is due to the expected reduction in hospital i.v. days. The sensitivity analysis suggests that even under pessimistic assumptions regarding lower levels of effectiveness of the intervention and lower unit costs per i.v. day, the adherence intervention is expected to remain dominant. This suggests that even if the CFHealthHub ACtiF trial does not meet its primary endpoint, the intervention may still produce cost savings for the health service.

Since this health economic analysis precedes the CFHealthHub ACTiF trial, there is considerable uncertainty regarding whether the findings of the analysis will concord with the data that will be collected within the trial itself. Invariably, such early modelling analyses are subject to the risk of reaching erroneous conclusions and rely on a weaker evidence base than would be available had the full trial been completed. It is therefore important to consider these evidential issues in the interpretation of the results of this analysis; these limitations are discussed briefly below.

(i) Clinical evidence to support the effectiveness of the adherence intervention

The most pertinent limitation of the evidence base is that the CFHealthHub ACTiF trial, which aims to assess the clinical benefit of the adherence intervention, has not yet begun. As such, there is currently no direct empirical evidence through which to quantify the benefits of the adherence intervention. Given this lack of evidence, the model uses the expected reduction in exacerbations used to inform the power calculations for the CFHealthHub ACTiF trial [11;17] as the basis for modelling expected treatment effects. Whilst this estimate reflects a legitimate prior belief, and forms the basis of the hypothesis that will be tested within the trial, there is a possibility that the anticipated reduction in exacerbations could be higher or lower than predicted. Nonetheless, the economic analysis presented here has a wider relevance in quantifying the potential gains that could be accrued through the implementation of adherence interventions which shift care from expensive hospital-based rescue to more economical community-based prevention. This analysis may therefore be useful in supporting the development and evaluation of other adherence interventions within the NHS or across other health care systems.

(ii) Transition probabilities and exacerbation rates are assumed to apply indefinitely

The model uses a single matrix of probabilities describing the trajectories of lung function across three FEV₁ strata in each treatment group. Whilst age is included as a covariate in the logit regression analyses, these are treated as time-independent parameters within the health economic model. In reality, FEV₁ transitions may be time-variant. Owing to the absence of long-term data on FEV₁ trajectories with and without the intervention, the model assumes that these trajectories remain constant with respect to time. It should be noted however, that the economic conclusions drawn from the analysis remain unchanged even if the intervention has no impact upon lung function decline (Table 3).

(iii) Treatment effect assumed to apply indefinitely

Given the preliminary nature of the health economic analysis and the current lack of evidence regarding the effectiveness of the adherence intervention, the model assumes that the treatment effect applies indefinitely over the patient's remaining lifetime. It may be the case that levels of adherence to antibiotic therapies may increase or wane over time following the introduction of the intervention.

The sensitivity analysis suggests that both health gains and cost savings are expected to be reduced over shorter intervals, although the intervention is expected to remain dominant irrespective of the time horizon and assumptions regarding the durability of the treatment effect.

(iv) Limitations in handling cost savings due to the CF banding tariff

Within the model, benefits and costs are captured through two different processes: (i) a direct reduction in the number of days spent receiving i.v. antibiotics, and; (ii) the impact of reduced exacerbations on subsequent FEV₁ trajectory. In England, CF care is currently funded via a mandatory tariff for specialist commissioning which is intended to reflect the severity of disease in individual patients; the UK CF banding tariff is intended to encapsulate both lung function and i.v. days. Consequently, an analysis which accounts only for changes in the CF tariff band would fail to fully reflect cost savings realised by the NHS due to fewer i.v. days spent in hospital; this would lead to an underestimate of the true cost-effectiveness of the adherence intervention. Alternatively, an analysis which includes CF banding costs as well as i.v. hospital costs, as has been assumed here, may overestimate the cost-savings associated with reducing exacerbations. It is anticipated that the data collection mechanisms within the CFHealthHub ACTiF trial will allow for a more sensitive and accurate analysis of the true costs associated with the adherence intervention based on the direct modelling of FEV₁ status and CF banding categories.

(v) Relationship between treatment costs and patient adherence

There is uncertainty regarding the relationship between the costs of treatment and patient adherence to those treatments. The base case analysis assumes that antibiotic treatment costs borne by the NHS are independent of patient adherence levels. It is possible that increasing adherence levels will also lead to increases in total NHS expenditure on antibiotic treatments: as patients become more adherent to therapy, they may require more frequent prescriptions. The consequence of this situation would be an increase in the total CF drugs bill, and the expected cost savings of increased adherence would be somewhat diminished. However, the sensitivity analyses indicate that even in the presence of very pessimistic assumptions regarding the relationship between treatment adherence and treatment costs, specifically a scenario whereby treatment costs borne by the NHS exactly reflect patient consumption of those treatments, the adherence intervention is expected to remain cost-saving (Table 3).

5. CONCLUSIONS

Based on an early health economic analysis using high quality registry data [1;15] and the estimated reduction in exacerbations used to inform the design of the CFHealthHub ACTiF trial [11], the adherence intervention is expected to produce additional health gains at a substantially lower cost than current CF care. The findings of the analysis should be revisited upon the completion of the full RCT. More broadly, the analysis suggests that considerable gains could be accrued through the

implementation of adherence interventions which shift care from hospital-based rescue to community-based prevention.

DATA AVAILABILITY STATEMENT

The model developed within this study is available from the corresponding author upon reasonable request. The authors confirm that all model inputs are presented in the paper.

ACKNOWLEDGEMENTS

This study represents an early evaluation undertaken as part of the CFHealthHub ACtiF programme, funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (grant number RP-PG-1212-20015). The authors would like to thank the CF Registry for providing access to data.

AUTHOR CONTRIBUTIONS

Paul Tappenden developed the health economic model. Susannah Sadler undertook the analyses of the CF Registry dataset. Martin Wildman advised on the design of the study and the evidence used to inform the model. All authors contributed to the preparation of this manuscript. Paul Tappenden will act as the overall guarantor for this work.

COMPLIANCE WITH ETHICAL STANDARDS

Dr Wildman has received support from Pari to speak at conferences about the importance of adherence. Dr Wildman has also received funding from Pari to travel to meetings with Pari about setting up a trial to understand whether increasing adherence improves outcomes in CF. Dr Wildman has received funding from Philips to support research using the Ineb nebuliser to understand how the device can be used to measure adherence. Dr Wildman has received speaker fees from Forrest to give independent talks at CF meetings around the UK about the importance of adherence. Paul Tappenden and Susannah Sadler have no conflicts of interest to declare.

REFERENCES

1. Cystic Fibrosis Trust. UK cystic fibrosis registry annual data report 2015. 1-66. Kent, CF Trust.
2. Davies JC, Alton EFWF, Bush A. Cystic fibrosis. *British Medical Journal* 2007; 335:1255-1259.
3. Cystic Fibrosis Trust, Cystic. Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. 1-102. 2009. London, CF Trust.
4. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: Challenges to self-management. *Journal of Cystic Fibrosis* 2009; 8(2):91-96.

5. Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, et al. Pulmonary medication adherence and healthcare utilization in cystic fibrosis. *Chest* 2014; 146(1):142-151.
6. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppert T et al. A new taxonomy for describing and defining adherence to medications. *British Journal of Pharmacology* 2012; 73(5):691-705.
7. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. *Chest* 2011; 140(2):425-432.
8. Hoo ZH, Curley R, Campbell MJ, Walters SJ, Hind D, Wildman MJ. Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence." *Patient Preference and Adherence* 2016;10:1-14.
9. Pugatsch T, Shoseyov D, Cohen-Cymbarknoh M, Hayut B, Armoni S, Griese M, et al. Adherence pattern to study drugs in clinical trials by patients with cystic fibrosis. *Paediatric Pulmonology* 2016; 51(2):143-146.
10. Demonceau J, Ruppert T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. *Drugs* 2013;73:545-562.
11. Wildman M, O'Cathain A, Michie S, Buchan I, Arden M, Bradley J et al. Development and evaluation of an intervention to support adherence to treatment in adults with cystic fibrosis (ACtiF): Study protocol. 1-148. 2014.
12. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 1-102. 2013. London, NICE.
13. Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C, Cantrell A. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic *Pseudomonas aeruginosa* lung infection in cystic fibrosis: systematic review and economic model. *Health Technology Assessment* 2013;17(56):1-181.
14. Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, et al. The cost effectiveness of dry powder antibiotics for the treatment of *Pseudomonas aeruginosa* in patients with cystic fibrosis. *Pharmacoeconomics* 2014; 32(2):159-172.
15. CF Trust. CF registry - individual patient data [held on file]. 2015.
16. NHS England. 2016/17 National tariff payment system - Monitor report. 1-90. 2016. London, NHSE.
17. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. *New England Journal of Medicine* 2006;354(3):229-240.
18. Bradley J, Blume S, Stafford M. Quality of life and health utility in patients with cystic fibrosis. *European Respiratory Society Conference* 2010.
19. Anyanwu A, McGuire A, Rogers C, Murday A. Assessment of quality of life in lung transplantation using a simple generic tool. *Thorax* 2001;56(3):218-222.
20. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. *European Respiratory Journal* 2007;29(3):522-526.
21. BMJ Group, RCPCH Publications Ltd and the Royal Pharmaceutical Society of Great Britain. *British National Formulary*. 2016.

22. Department of Health. NHS Reference Costs 2014/15. 2015. London, DH.
23. Jung J. Estimating Markov transition probabilities between health states in the HRS dataset. Working paper - Towson University. 2006.
24. Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. *Journal of Cystic Fibrosis* 2012; 11(6):461-479.
25. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *American Journal of Respiratory Critical Care Medicine* 2009; 180(9):802-808.
26. Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Medical Research Methodology* 2012; 12(9).

Figure 1: Model structure




Figure 2: Cost-effectiveness plane




Table 1: Model parameters

| Parameter | Distribution | Parameter 1 | Parameter 2 | Mean | Source |
|---|--------------|-------------|-------------|-------|--|
| General parameters | | | | | |
| Time horizon (years) | n/a | - | - | 84 | n/a |
| Cycle length (years) | n/a | - | - | 1 | n/a |
| Start age (years) | n/a | - | - | 16 | Assumption |
| Discount rate QALYs | n/a | - | - | 3.50% | NICE Methods Guide [12] |
| Discount rate costs | n/a | - | - | 3.50% | |
| Initial distribution | | | | | |
| FEV ₁ ≥70% | Dirichlet | 2891.00 | 5715.00 | 0.51 | CF Registry dataset [15] |
| FEV ₁ 40%-60% | Dirichlet | 1965.00 | 5715.00 | 0.34 | |
| FEV ₁ <40% | Dirichlet | 859.00 | 5715.00 | 0.15 | |
| Post-transplant | - | - | - | 0 | Assumption |
| Dead | - | - | - | 0 | |
| Transition probabilities – current clinical care | | | | | |
| FEV ₁ ≥70% to FEV ₁ ≥70% | Dirichlet | 6056.33 | 6999.00 | 0.87 | Logit model fitted to CF Registry dataset [15] |
| FEV ₁ ≥70% to FEV ₁ 40%-60% | Dirichlet | 920.69 | 6999.00 | 0.13 | |
| FEV ₁ ≥70% to FEV ₁ <40% | Dirichlet | 21.98 | 6999.00 | 0.00 | |
| FEV ₁ 40%-60% to FEV ₁ ≥70% | Dirichlet | 502.08 | 3743.00 | 0.13 | |
| FEV ₁ 40%-60% to FEV ₁ 40%-60% | Dirichlet | 2860.77 | 3743.00 | 0.76 | |
| FEV ₁ 40%-60% to FEV ₁ <40% | Dirichlet | 380.15 | 3743.00 | 0.10 | |
| FEV ₁ <40% to FEV ₁ ≥70% | Dirichlet | 35.37 | 1350.00 | 0.03 | |
| FEV ₁ <40% to FEV ₁ 40%-60% | Dirichlet | 185.16 | 1350.00 | 0.14 | |
| FEV ₁ <40% to FEV ₁ <40% | Dirichlet | 1129.47 | 1350.00 | 0.84 | |
| Transition probabilities – post-intervention | | | | | |
| FEV ₁ ≥70% to FEV ₁ ≥70% | Dirichlet | 6100.83 | 6999.00 | 0.87 | Logit model fitted to CF Registry data [15] including ACtiF trial power calculation [11] |
| FEV ₁ ≥70% to FEV ₁ 40%-60% | Dirichlet | 877.38 | 6999.00 | 0.13 | |
| FEV ₁ ≥70% to FEV ₁ <40% | Dirichlet | 20.79 | 6999.00 | 0.00 | |
| FEV ₁ 40%-60% to FEV ₁ ≥70% | Dirichlet | 545.51 | 3743.00 | 0.15 | |
| FEV ₁ 40%-60% to FEV ₁ 40%-60% | Dirichlet | 2849.04 | 3743.00 | 0.76 | |
| FEV ₁ 40%-60% to FEV ₁ <40% | Dirichlet | 348.45 | 3743.00 | 0.09 | |
| FEV ₁ <40% to FEV ₁ ≥70% | Dirichlet | 34.65 | 1350.00 | 0.03 | |
| FEV ₁ <40% to FEV ₁ 40%-60% | Dirichlet | 182.04 | 1350.00 | 0.13 | |

| Parameter | Distribution | Parameter 1 | Parameter 2 | Mean | Source |
|--|--------------|-------------|-------------|-------|--|
| FEV ₁ <40% to FEV ₁ <40% | Dirichlet | 1133.30 | 1350.00 | 0.84 | |
| Transplant rate | | | | | |
| Probability transplant/year (FEV ₁ <40%) | Normal | 0.004 | 0.000 | 0.004 | Based on CF Registry [1] and US CF Foundation |
| i.v. days (exacerbations) – baseline | | | | | |
| i.v. days - FEV ₁ ≥70% | Beta | 1802.23 | 42817.94 | 0.04 | Observed data from CF registry dataset [15] |
| i.v. days - FEV ₁ 40%-60% | Beta | 3134.66 | 32608.88 | 0.09 | |
| i.v. days - FEV ₁ <40% | Beta | 1184.13 | 6181.86 | 0.16 | |
| i.v. days (exacerbations) – post-intervention | | | | | |
| Relative risk of exacerbation requiring i.v. treatment | Log normal | 0.45 | 0.09 | 0.45 | Power calculation based on Elkins et al [17]. Additional uncertainty included in 95% CI. |
| i.v. days - FEV ₁ ≥70% | N/a | - | 0.02 | - | Calculated using baseline i.v. days and relative risk of exacerbation requiring i.v. treatment |
| i.v. days - FEV ₁ 40%-60% | N/a | - | 0.04 | - | |
| i.v. days - FEV ₁ <40% | N/a | - | 0.07 | - | |
| Health-related quality of life | | | | | |
| Utility FEV ₁ ≥70% | Beta | 108.52 | 17.08 | 0.86 | Bradley et al [18] |
| Disutility FEV ₁ ≥70% to FEV ₁ 40-69% | Beta | 4.11 | 72.01 | 0.05 | |
| Disutility FEV ₁ 40%-69% to FEV ₁ <40% | Beta | 12.60 | 61.51 | 0.17 | |
| Disutility i.v. exacerbation | Beta | 3.48 | 16.53 | 0.17 | |
| Utility - post-transplant | Beta | 319.31 | 65.40 | 0.83 | Anyanwu et al [19] |
| Survival | | | | | |
| Gompertz - constant | Normal | 0.004 | 0.00 | 0.00 | Parametric survivor function fitted to data reported by Dodge et al [20] |
| Gompertz - gamma | Normal | 0.06 | 0.01 | 0.06 | |
| CF banding by FEV₁ % | | | | | |
| FEV ₁ ≥70% - Proportion band 1 | Dirichlet | 886 | 4418.00 | 0.20 | CF Registry dataset [15] |
| FEV ₁ ≥70% - Proportion band 1a | Dirichlet | 83.00 | 4418.00 | 0.02 | |
| FEV ₁ ≥70% - Proportion band 2 | Dirichlet | 1063.00 | 4418.00 | 0.24 | |
| FEV ₁ ≥70% - Proportion band 2a | Dirichlet | 1497.00 | 4418.00 | 0.34 | |
| FEV ₁ ≥70% - Proportion band 3 | Dirichlet | 799.00 | 4418.00 | 0.18 | |
| FEV ₁ ≥70% - Proportion band 4 | Dirichlet | 75.00 | 4418.00 | 0.02 | |
| FEV ₁ ≥70% - Proportion band 5 | Dirichlet | 15.00 | 4418.00 | 0.00 | |
| FEV ₁ 40%-60% - Proportion band 1 | Dirichlet | 115.00 | 2290.00 | 0.05 | |

| Parameter | Distribution | Parameter 1 | Parameter 2 | Mean | Source |
|---|--------------|-------------|-------------|------------|--|
| FEV ₁ 40%-60% - Proportion band 1a | Dirichlet | 28.00 | 2290.00 | 0.01 | |
| FEV ₁ 40%-60% - Proportion band 2 | Dirichlet | 250.00 | 2290.00 | 0.11 | |
| FEV ₁ 40%-60% - Proportion band 2a | Dirichlet | 807.00 | 2290.00 | 0.35 | |
| FEV ₁ 40%-60% - Proportion band 3 | Dirichlet | 787.00 | 2290.00 | 0.34 | |
| FEV ₁ 40%-60% - Proportion band 4 | Dirichlet | 247.00 | 2290.00 | 0.11 | |
| FEV ₁ 40%-60% - Proportion band 5 | Dirichlet | 56.00 | 2290.00 | 0.02 | |
| FEV ₁ <40% - Proportion band 1 | Dirichlet | 20.00 | 947.00 | 0.02 | |
| FEV ₁ <40% - Proportion band 1a | Dirichlet | 6.00 | 947.00 | 0.01 | |
| FEV ₁ <40% - Proportion band 2 | Dirichlet | 60.00 | 947.00 | 0.06 | |
| FEV ₁ <40% - Proportion band 2a | Dirichlet | 234.00 | 947.00 | 0.25 | |
| FEV ₁ <40% - Proportion band 3 | Dirichlet | 310.00 | 947.00 | 0.33 | |
| FEV ₁ <40% - Proportion band 4 | Dirichlet | 225.00 | 947.00 | 0.24 | |
| FEV ₁ <40% - Proportion band 5 | Dirichlet | 92.00 | 947.00 | 0.10 | |
| High cost drug use | | | | | |
| Dornase alpha | Beta | 3949.00 | 2660.00 | 0.60 | CF Registry dataset [15] |
| Tobramycin | Beta | 779.00 | 5830.00 | 0.12 | |
| Aztreonam | Beta | 235.00 | 6374.00 | 0.04 | |
| Colistimethate sodium (Colomycin) | Beta | 2555.00 | 4054.00 | 0.39 | |
| Colistimethate sodium (Promixin) | Beta | 1602.00 | 5007.00 | 0.24 | |
| Tobi+Podhaler | Beta | 779.00 | 5830.00 | 0.12 | |
| CF banding costs | | | | | |
| Cost band 1 | Fixed | £5,033 | - | £5,033 | NHS England Monitor report 2016 Annex A [16] |
| Cost band 1a | Fixed | £7,447 | - | £7,447 | |
| Cost band 2 | Fixed | £7,447 | - | £7,447 | |
| Cost band 2a | Fixed | £12,036 | - | £12,036 | |
| Cost band 3 | Fixed | £18,422 | - | £18,422 | |
| Cost band 4 | Fixed | £33,224 | - | £33,224 | |
| Cost band 5 | Fixed | £40,054 | - | £40,054 | |
| Drug costs | | | | | |
| Dornase alpha | Fixed | £6,044.04 | - | £6,044.04 | British National Formulary 2016 [21] |
| Tobramycin | Fixed | £6,016.25 | - | £6,016.25 | |
| Aztreonam | Fixed | £14,228.64 | - | £14,228.64 | |
| Colistimethate sodium (Colomycin) | Fixed | £2,366.82 | - | £2,366.82 | |

| Parameter | Distribution | Parameter 1 | Parameter 2 | Mean | Source |
|---|--------------|-------------|-------------|------------|--|
| Colistimethate sodium (Promixin) | Fixed | £8,181.60 | - | £8,181.60 | |
| Tobi+Podhaler | Fixed | £11,674.96 | - | £11,674.96 | |
| Adherence intervention - marginal costs | | | | | |
| Once-only data transfer hardware | Fixed | £121.20 | - | £121.20 | Personal communication - Martin Wildman, Sheffield Teaching Hospitals, England, 2016 |
| Annual data transfer | Fixed | £158.40 | - | £583.44 | |
| Other costs | | | | | |
| Cost i.v. day | Normal | £361.68 | £77.48 | £361.68 | NHS Reference Costs 2014/15 - Long stay bronchiectasis, CC score 0 [22] |
| Proportion of i.v. days in hospital | Beta | 93,455.00 | 78,452.00 | 0.54 | Personal communication - Tim Gleeson, Sheffield Teaching Hospitals, England, 2016 |
| Cost of i.v. ceftazidime and tobramycin per day | Fixed | £71.99 | - | £71.99 | Personal communication - Martin Wildman, Sheffield Teaching Hospitals, England, 2015 |
| Cost transplant | Normal | £40,000.00 | £4,000.00 | £40,000.00 | Personal communication - Kim Cox, NHS England, 2015 |

Param – parameter; n/a - not applicable; QALY – quality-adjusted life year; i.v. intravenous; FEV₁ – forced expiratory volume in 1 second; NICE – National Institute for Health and Care Excellence; NHS – National Health Service; CF – cystic fibrosis; CC – comorbidities and complications

Table 2: Central estimates of cost-effectiveness (probabilistic)

| Option | QALYs | Costs | Incremental QALYs | Incremental Costs | Incremental cost per QALY gained |
|------------------------|-------|----------|-------------------|-------------------|----------------------------------|
| Adherence intervention | 12.24 | £431,261 | 0.19 | -£64,078 | Dominating |
| Current care | 12.05 | £495,338 | - | - | - |

QALY – quality-adjusted life year; ICER – incremental cost-effectiveness ratio

Table 3: Deterministic sensitivity analysis results

| Scenario | Adherence intervention versus current care | | ICER |
|---|--|-------------------|------------|
| | Incremental QALYs | Incremental costs | |
| Base case | 0.19 | £63,832 | dominating |
| Undiscounted results | 0.34 | £106,715 | dominating |
| 5-year time horizon | 0.04 | £16,623 | dominating |
| 10-year time horizon | 0.08 | £30,871 | dominating |
| 20-year time horizon | 0.15 | £50,257 | dominating |
| Intervention impacts on i.v. days only | 0.12 | £59,314 | dominating |
| 25% reduction in exacerbation rate RR (relative risk reduction=0.58) | 0.16 | £47,213 | dominating |
| 50% reduction in exacerbation rate RR (relative risk reduction=0.72) | 0.13 | £30,594 | dominating |
| Cost i.v. days halved | 0.19 | £38,263 | dominating |
| Cost of adherence intervention doubled | 0.19 | £54,796 | dominating |
| i.v. disutility doubled | 0.32 | £63,832 | dominating |
| i.v. disutility halved | 0.13 | £63,832 | dominating |
| Treatment costs assumed to exactly reflect patient consumption based on Daniels et al [3] and Demonceau et al [6] | 0.19 | £25,247 | dominating |

i.v. – intravenous; RR – relative risk; QALY – quality-adjusted life year; ICER – incremental cost-effectiveness ratio